Related Experiment Video

Updated: Jul 8, 2025

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
07:13

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

Published on: April 12, 2021

4.3K

The interventions to improve medication adherence in coronary heart disease patient: A systematic review

Amanda Marselin1,2, Lia Amalia1, Lucia K Dinarti3

  • 1School of Pharmacy, Institut Teknologi Bandung, Indonesia.

Journal of the Saudi Heart Association
|December 20, 2023
PubMed

Insights

Improving medication adherence in coronary heart disease (CHD) patients is crucial. Interventions, especially m-health, effectively enhance adherence, but long-term strategies require attention.

Area of Science:

  • Cardiology
  • Health Informatics
  • Public Health

Background:

  • Medication adherence significantly impacts clinical outcomes and quality of life for patients with coronary heart disease (CHD).
  • Non-adherence leads to suboptimal treatment results and increased healthcare costs.
  • Effective interventions are needed to improve medication adherence in CHD patients.

Purpose of the Study:

  • To systematically review and describe the effectiveness of interventions aimed at improving medication adherence in CHD patients.
  • To identify common intervention strategies and their impact on adherence rates.

Main Methods:

  • A systematic review was conducted using Scopus and PubMed databases.
  • PRISMA guidelines were followed for article selection, with 31 articles included from an initial 788.
  • The primary outcome measured was medication adherence in CHD patients.

Main Results:

  • Mobile health (m-health) interventions, including text messages and smartphone applications, were most common (15 articles) and effectively improved adherence.
  • Non-m-health interventions such as self-efficacy programs, health worker education, and clinical pharmacy services also showed positive effects.
  • Some studies indicated a decrease in adherence over long follow-up periods, highlighting the need for sustained management.

Conclusions:

  • Various programs, including m-health and non-m-health approaches, can enhance medication adherence in CHD patients.
  • Modifying interventions to improve communication, motivation, and knowledge is key to sustained adherence.
  • Long-term adherence management requires ongoing attention from healthcare professionals.
Abstract

Keywords:
Artery diseaseCardiovascularEducationMedication managementm-health

More Related Videos

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program04:24

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program

Published on: April 19, 2019

11.6K
Using Continuous Data Tracking Technology to Study Exercise Adherence in Pulmonary Rehabilitation09:42

Using Continuous Data Tracking Technology to Study Exercise Adherence in Pulmonary Rehabilitation

Published on: November 8, 2013

13.6K

Related Concept Videos

Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
45
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
341
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
519
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
594
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
394